The Vascular Marker Soluble Fms-Like Tyrosine Kinase 1 Is Associated With Disease Severity and Adverse Outcomes in Chronic Heart Failure

Journal of the American College of Cardiology

Volumn 58, Issue 4, 2011, Pages 386-394

  Ky, Bonnie ^a   French, Benjamin ^a   Ruparel, Kosha ^a   Sweitzer, Nancy K ^b   Fang, James C ^c   Levy, Wayne C ^d   Sawyer, Douglas B ^e   Cappola, Thomas P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e VANDERBILT UNIVERSITY   (United States)

Author keywords

heart failure; placental growth factor; soluble Flt 1

Indexed keywords

BIOLOGICAL MARKER; PLACENTA PROTEIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

AGED; ARTICLE; BLOOD; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED;

AGED; BIOLOGICAL MARKERS; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PREGNANCY PROTEINS; SEVERITY OF ILLNESS INDEX; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

MLCS; MLOWN;

EID: 80053298819     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.03.032     Document Type: Article

References (44)

1. Oka, T., Komuro, I., Molecular mechanisms underlying the transition of cardiac hypertrophy to heart failure. Circ J 72:Suppl A (2008), A13–A16.
2. Lip, G.Y., Chung, I., Vascular endothelial growth factor and angiogenesis in heart failure. J Card Fail 11 (2005), 285–287.
3. Hsieh, P.C., Davis, M.E., Lisowski, L.K., Lee, R.T., Endothelial-cardiomyocyte interactions in cardiac development and repair. Annu Rev Physiol 68 (2006), 51–66.
4. Helotera, H., Alitalo, K., The VEGF family, the inside story. Cell 130 (2007), 591–592.
5. Carmeliet, P., Angiogenesis in life, disease and medicine. Nature 438 (2005), 932–936.
6. Abraham, D., Hofbauer, R., Schafer, R., et al. Selective downregulation of VEGF-A(165), VEGF-R(1), and decreased capillary density in patients with dilative but not ischemic cardiomyopathy. Circ Res 87 (2000), 644–647.
7. Izumiya, Y., Shiojima, I., Sato, K., Sawyer, D.B., Colucci, W.S., Walsh, K., Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 47 (2006), 887–893.
8. Pepe, M., Mamdani, M., Zentilin, L., et al. Intramyocardial VEGF-B167 gene delivery delays the progression towards congestive failure in dogs with pacing-induced dilated cardiomyopathy. Circ Res 106 (2010), 1893–1903.
9. Zhao, Q., Ishibashi, M., Hiasa, K., Tan, C., Takeshita, A., Egashira, K., Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension 44 (2004), 264–270.
10. Luttun, A., Tjwa, M., Carmeliet, P., Placental growth factor (PlGF) and its receptor flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann N Y Acad Sci 979 (2002), 80–93.
11. Onoue, K., Uemura, S., Takeda, Y., et al. Usefulness of soluble Fms-like tyrosine kinase-1 as a biomarker of acute severe heart failure in patients with acute myocardial infarction. Am J Cardiol 104 (2009), 1478–1483.
12. Heeschen, C., Dimmeler, S., Fichtlscherer, S., et al. Prognostic value of placental growth factor in patients with acute chest pain. JAMA 291 (2004), 435–441.
13. Levine, R.J., Maynard, S.E., Qian, C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350 (2004), 672–683.
14. Noori, M., Donald, A.E., Angelakopoulou, A., Hingorani, A.D., Williams, D.J., Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 122 (2010), 478–487.
15. Iwama, H., Uemura, S., Naya, N., et al. Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction. J Am Coll Cardiol 47 (2006), 1559–1567.
16. Lenderink, T., Heeschen, C., Fichtlscherer, S., et al. Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes. J Am Coll Cardiol 47 (2006), 307–311.
17. Belgore, F.M., Blann, A.D., Lip, G.Y., sFlt-1, a potential antagonist for exogenous VEGF. Circulation 102 (2000), E108–E109.
18. Kodama, Y., Kitta, Y., Nakamura, T., et al. Atorvastatin increases plasma soluble Fms-like tyrosine kinase-1 and decreases vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction. J Am Coll Cardiol 48 (2006), 43–50.
19. Nakamura, T., Funayama, H., Kubo, N., et al. Elevation of plasma placental growth factor in the patients with ischemic cardiomyopathy. Int J Cardiol 131 (2009), 186–191.
20. Ky, B., Kimmel, S.E., Safa, R.N., et al. Neuregulin-1beta is associated with disease severity and adverse outcomes in chronic heart failure. Circulation 120 (2009), 310–317.
21. Yeo, K.T., Wu, A.H., Apple, F.S., et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the biosite triage BNP assay. Clin Chim Acta 338 (2003), 107–115.
22. Di Marco, G.S., Reuter, S., Hillebrand, U., et al. The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am Soc Nephrol 20 (2009), 2235–2245.
23. Maynard, S.E., Min, J.Y., Merchan, J., et al. Excess placental soluble Fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111 (2003), 649–658.
24. Onoue, K., Uemura, S., Takeda, Y., et al. Reduction of circulating soluble Fms-like tyrosine kinase-1 plays a significant role in renal dysfunction-associated aggravation of atherosclerosis. Circulation 120 (2009), 2470–2477.
25. Schrijvers, B.F., Flyvbjerg, A., De Vriese, A.S., The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65 (2004), 2003–2017.
26. Giordano, F.J., Gerber, H.P., Williams, S.P., et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A 98 (2001), 5780–5785.
27. Levy, W.C., Mozaffarian, D., Linker, D.T., et al. The Seattle heart failure model: prediction of survival in heart failure. Circulation 113 (2006), 1424–1433.
28. Heagerty, P.J., Lumley, T., Pepe, M.S., Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56 (2000), 337–344.
29. R Development Core Team. R: a language and environment for statistical computing. 2010. R version 2.12.0. http://www.R-project.org Accessed October 15, 2010.
30. Venables, W.N., Ripley, B.D., Modern Applied Statistics with S-PLUS., 2nd edition, 1997, Springer, New York, NY, 220–221.
31. Therneau, T., Lumley, T., Survival: survival analysis, including penalized likelihood. 2009. R package version 2.35-4. http://www.R-project.org Accessed October 15, 2010.
32. Heagerty, P.J., Saha, P., survivalROC: time-dependent ROC curve estimation from censored survival data. 2006. R package version 1.0.0. http://www.R-project.org Accessed October 15, 2010.
33. Pradhan, A.D., Manson, J.E., Rossouw, J.E., et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the women's health initiative observational study. JAMA 288 (2002), 980–987.
34. Denizot, Y., Leguyader, A., Cornu, E., et al. Release of soluble vascular endothelial growth factor receptor-1 (sFlt-1) during coronary artery bypass surgery. J Cardiothorac Surg, 2, 2007, 38.
35. Aref, S., El Sherbiny, M., Goda, T., Fouda, M., Al Askalany, H., Abdalla, D., Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient outcome. Hematology 10 (2005), 131–134.
36. Shapiro, N.I., Yano, K., Okada, H., et al. A prospective, observational study of soluble FLT-1 and vascular endothelial growth factor in sepsis. Shock 29 (2008), 452–457.
37. Rini, B.I., Michaelson, M.D., Rosenberg, J.E., et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 26 (2008), 3743–3748.
38. Robak, E., Sysa-Jedrzejewska, A., Robak, T., Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus. Mediators Inflamm 12 (2003), 293–298.
39. Tammela, T., Enholm, B., Alitalo, K., Paavonen, K., The biology of vascular endothelial growth factors. Cardiovasc Res 65 (2005), 550–563.
40. Belgore, F.M., Blann, A.D., Li-Saw-Hee, F.L., Beevers, D.G., Lip, G.Y., Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol 87 (2001), 805–807.
41. Walsh, K., Shiojima, I., Cardiac growth and angiogenesis coordinated by intertissue interactions. J Clin Invest 117 (2007), 3176–3179.
42. Willett, C.G., Duda, D.G., di Tomaso, E., et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 27 (2009), 3020–3026.
43. Hlatky, M.A., Greenland, P., Arnett, D.K., et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119 (2009), 2408–2416.
44. Morrow, D.A., de Lemos, J.A., Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115 (2007), 949–952.